Business context and reporting period
This Form 10-Q covers the quarter ended September 30, 2015, and was filed by Galena Biopharma, Inc. (not SELLAS Life Sciences Group, Inc.). Galena was a clinical-stage biopharmaceutical company focused on oncology candidates, including NeuVax, GALE-301/302 and GALE-401. The company decided to sell or otherwise divest its commercial business, including Abstral and Zuplenz, and reported it as discontinued operations.
Financial performance and liquidity
| Metric | Three months ended September 30 | Nine months ended September 30 |
|---|---|---|
| R&D expense | 2015: $5.7 million; 2014: $7.0 million | 2015: $18.8 million; 2014: $21.5 million |
| G&A expense | 2015: $2.9 million; 2014: $3.5 million | 2015: $7.9 million; 2014: $12.7 million |
| Operating loss from continuing operations | 2015: $8.6 million; 2014: $10.6 million | 2015: $26.6 million; 2014: $34.2 million |
| Net loss | 2015: $18.0 million; 2014: $6.2 million | 2015: $44.2 million; 2014: $28.7 million |
| Net loss per share | 2015: $0.11; 2014: $0.05 | 2015: $0.29; 2014: $0.25 |
Commercial discontinued operations generated revenue of $2.2 million in the quarter and $8.3 million over nine months in 2015, versus $1.6 million and $6.1 million, respectively, in 2014. Discontinued-operation losses were $11.7 million for the quarter and $16.1 million for nine months; each 2015 period included an $8.1 million impairment charge on commercial assets held for sale.
Cash and cash equivalents were $34.8 million at September 30, 2015, compared with $23.7 million at December 31, 2014. Nine-month operating cash use was $32.9 million, investing cash use was $0.8 million, and financing provided $44.9 million. Financing included $47.4 million net proceeds from common stock issuance and related activity. Current assets were $54.2 million and current liabilities $37.1 million. Total debt was $5.7 million, including $4.2 million current; the loan carried an 8.45% fixed coupon and was scheduled to mature in November 2016.
Warrant liabilities rose to $16.7 million from $5.4 million at year-end; quarter-to-quarter fair-value changes materially affected reported non-operating results. The company had 161.9 million common shares outstanding at October 31, 2015.
Material changes and management commentary
- Net loss increased year over year, principally reflecting the commercial-asset impairment and a much smaller warrant fair-value gain than in 2014. Continuing operating losses declined as R&D and G&A expenses fell.
- Management attributed lower R&D spending partly to completion of enrollment in the Phase 3 PRESENT trial and expected PRESENT costs to decline as it moved into monitoring and follow-up, potentially offset by other trial spending.
- PRESENT was fully enrolled with 758 patients; the primary endpoint was expected in 2018. Management planned the NeuVax DCIS trial for late 2015 or early 2016 and a gastric-cancer trial in India for 2016.
- Preliminary GALE-301 Phase 2a results showed estimated two-year disease-free survival of 85.7% in the 1,000-mcg group versus 33.6% in controls (p<0.02). The filing cautions that the study was not powered to establish efficacy.
- GALE-401 Phase 2 results reported an overall platelet response rate of 78% (14 of 18 patients); management expected to present more mature data in December 2015.
- Management expected further discontinued-operation losses in the fourth quarter while seeking a buyer. It provided no quantified cash-runway or earnings guidance and noted that funding could depend on equity financing, research funding, or partnership payments.
Risks, contingencies, and unusual items
- The divestiture may not close, may yield limited proceeds, and could incur transaction, employee-separation, or other costs. If commercial operations are sold or discontinued, the company said it would have no recurring revenue until a product candidate receives marketing approval.
- Litigation included securities and derivative actions; the company recorded no liability for those claims and said insurers were reimbursing a significant portion of defense costs while reserving coverage rights. The company also disclosed an SEC investigation concerning use of outside investor-relations professionals and said it was cooperating.
- After quarter-end, on October 23, 2015, Galena and Orexo settled Abstral patent litigation with Actavis. The agreement permits generic or authorized-generic entry in June 2018 or earlier in certain circumstances; financial terms were confidential.
- Galena highlighted foreign-trial exposure: approximately 39% of PRESENT sites and 44% of randomized patients were in Russia and Ukraine, where political conditions could disrupt trial activity.
- Other risks include continued operating cash use, dependence on future financing or partnerships, potential dilution from warrants and stock issuance, and warrant-liability volatility.
Important facts for investors to verify
- Confirm the filing entity: this is Galena Biopharma’s 2015 third-quarter 10-Q, despite the request metadata naming SELLAS Life Sciences Group.
- Track progress, endpoint timing, and trial continuity for PRESENT, including risks at Russian and Ukrainian sites; verify subsequent clinical updates rather than treating estimates as established efficacy.
- Verify whether the commercial-business divestiture closed, the proceeds and costs, and the resulting revenue and cash profile.
- Review cash burn, debt repayment requirements, and financing needs alongside the $34.8 million quarter-end cash balance.
- Assess warrant-liability remeasurement and potential share dilution; compare actual subsequent share counts and financing terms.
- Follow developments in the disclosed securities/derivative litigation, SEC investigation, and Abstral settlement and generic-entry timing.